Gastric cancer treatment development shifting to mAbs
17 March 2016 | By Victoria White
The dominance of small molecules in the gastric cancer treatment space could be about to give way to monoclonal antibodies, according to GBI Research...
List view / Grid view
News
Allergan files ANDA to the FDA for generic Abraxane
17 March 2016 | By Victoria White
Allergan believes it is a first applicant to file an ANDA for generic Abraxane and, should it be approved, may get 180 days of generic market exclusivity...
Sir Andrew Witty to retire as CEO of GSK
17 March 2016 | By Victoria White
GSK has announced that Sir Andrew Witty, CEO, has indicated to the Board his intention to retire from the company in early 2017...
GSK’s Advair Diskus achieves primary endpoint in LABA safety study
17 March 2016 | By Victoria White
The VESTRI study compared Advair Diskus to fluticasone propionate monotherapy in children aged 4 – 11 years who have asthma...
First patient dosed in Halozyme’s PEGPH20 pancreatic cancer trial
17 March 2016 | By Victoria White
The trial will study PEGPH20 in combination with nab-paclitaxel and gemcitabine in patients with tumours that accumulate high levels of hyaluronan...
Amgen wins drug patent case against Sanofi and Regeneron
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
NICE says ‘no’ to talimogene laherparepvec in melanoma
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
Vaxon completes enrolment in Phase IIb trial of Vx-001 in NSCLC
16 March 2016 | By Victoria White
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides...
FDA advisory committee adopts a positive review of Abbott’s Absorb stent
16 March 2016 | By Victoria White
Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease. It dissolves completely after 2 to 3 years...
Freedom to evolve with Tecan’s Freedom EVO® 75
15 March 2016 | By Tecan
Researchers at the Complutense University of Madrid are using directed evolution techniques to develop new enzymes for a variety of bioprocessing applications...
Quotient Clinical incorporates Japanese bridging into a Translational Pharmaceutics® program
15 March 2016 | By Quotient Clinical
Quotient Clinical has announced the completion of its first clinical program involving Japanese healthy volunteers...
Verona Pharma announces positive headline data from RPL554 trial
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
Peptide vaccines and immuno-oncology products hold promise in glioblastoma
15 March 2016 | By Victoria White
According to GlobalData analysts, hopes for improved therapies for glioblastoma have turned to Opdivo and drugs combining peptide vaccines with immuno-oncology products...
Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial
15 March 2016 | By Victoria White
Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...
First patient treated in trial of ReNeuron’s retinitis pigmentosa cell therapy
ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration...
